96.40 +0.20 (0.21%)
After hours: 6:20PM EST
When the husband-and-wife team of Dr. Ugur Sahin and Dr. Ozlem Tureci started BioNTech (NASDAQ: BNTX), they envisioned a diversified European pharmaceutical company focused on cutting-edge cancer treatments. With the authorization and distribution of Comirnaty, the COVID-19 vaccine it developed with Pfizer (NYSE: PFE), the company will have all the resources it needs to pursue its goal. A current $26 billion market capitalization is pricing in plenty of vaccine success, but BioNTech still may not be getting the credit it deserves for the other drugs in its pipeline using its revolutionary new messenger RNA (mRNA) approach.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Pfizer, BioNTech, Moderna and AstraZeneca
Fifteen billion dollars: That's how much Pfizer (NYSE: PFE) projected last month in its Q4 update that it will make this year from its COVID-19 vaccine, BNT162b2. Since Pfizer's update, the U.S. government has ordered another 100 million doses of BNT162b2. Pfizer and BioNTech announced last week that they've begun a study to evaluate a third dose of BNT162b2.